Artificial IntelligenceHigh Priority (8/10)Usa

Eli Lilly Doubles Down on Insilico Medicine AI Partnership, Bets Up to $2.75 Billion

Eli Lilly is expanding its partnership with Insilico Medicine, committing $115 million upfront and up to $2.75 billion in total to use the biotech's AI-powered machine learning platforms for developing oral drugs against various diseases.

Key Points

  • Lilly committing $115 million upfront with potential total deal value up to $2.75 billion
  • Partnership focuses on AI-driven oral drug development for multiple diseases
  • Builds on Lilly's existing AI infrastructure including NVIDIA supercomputer partnership
  • Insilico's AI platform complements Lilly's clinical development expertise

Full Details

Eli Lilly is significantly expanding its AI-driven drug discovery capabilities through a deepened partnership with Insilico Medicine. The pharmaceutical giant is committing $115 million upfront and potentially up to $2.75 billion in total to leverage Insilico's AI and machine learning platforms for oral drug development across multiple diseases. The collaboration will involve multiple R&D programs centered on targets of Lilly's choosing, utilizing Insilico's AI-enabled engine. This deal builds on Lilly's broader AI push, including a partnership last year with NVIDIA to build a supercomputer specifically for optimizing drug discovery and shortening development timelines. Andrew Adams, Lilly's group vice president of Molecule Discovery, stated that Insilico is 'a powerful complement to Lilly's deep expertise in clinical development.'

Why It Matters

The substantial investment signals pharmaceutical companies' growing confidence in AI to accelerate drug discovery, potentially reducing development timelines and costs while increasing the pace of bringing new treatments to market.

Sourcebiospace.com

Get stories like this delivered daily

AI-curated news, personalized to your interests. Zero noise.

Start 7-Day Free Trial →

More in Artificial Intelligence